Hence, therapeutics targeting the NLRP3 inflammasome could be employed in the treatment of T2D and obesity because considerable numbers of studies have shown the effectiveness of this strategy. Here, NLRP3 is linked to obesity due to melanocortin 4 receptor deficiency.